Jade Biosciences, Inc.
Jade Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing novel biologic therapies for autoimmune diseases. Its pipeline centers on monoclonal antibodies designed to improve dosing convenience, maintain a comparable safety profile, and potentially deliver stronger clinical activity than existing approaches.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaJADE101 and JADE201 are the company’s main clinical-stage antibody programs targeting autoimmune disease pathways.
JADE301 and other discovery-stage assets represent earlier-stage programs intended to expand the pipeline.
The company seeks to in-license or option third-party biologic candidates and related intellectual property.
Asiakkaat
Jade Biosciences does not yet sell approved products, so its near-term “customers” are primarily regulators, clinical trial participants, and development partners rather than commercial buyers. If its programs succeed, the eventual end customers would be physicians, hospitals, and patients in autoimmune disease markets such as IgA nephropathy and rheumatoid arthritis. The company’s value proposition is aimed at treatment settings where improved dosing, convenience, and clinical activity can differentiate a biologic from existing therapies.
Patients enrolled in Phase 1 and future studies who generate safety, PK, and proof-of-concept data.
Nephrologists, rheumatologists, and other specialists who would prescribe approved products if development succeeds.
Potential licensing or collaboration partners that may fund development or commercialize assets.
FDA and foreign regulators that determine whether programs can advance into and through clinical development.
Strategia
The company’s strategy is to build a differentiated autoimmune-disease pipeline around biologics that can show better dosing convenience and competitive pharmacology. Near term, it is prioritizing JADE101 clinical execution, while JADE201 and JADE301 broaden the platform and create optionality for future indications and partnerships.
The company says it is substantially dependent on JADE101 and is investing most resources there.
A broader indication set could create a larger commercial opportunity if early data are positive.
Additional assets reduce single-program dependence and increase the chance of finding a differentiated candidate.
Maantiede
Jade Biosciences is headquartered in the United States and operates as a U.S.-based development-stage biotech company. The filings disclose a Phase 1 JADE101 trial in New Zealand, showing that clinical execution is already international even though the company has no product revenue and no disclosed geographic sales mix. Its geography is therefore driven more by trial sites, CRO/CMO relationships, and regulatory pathways than by commercial market presence.
Riskit
Jade Biosciences is a preclinical/clinical-stage biotech with no approved products, so its business depends on successful trial outcomes, regulatory approvals, and access to capital. The company also relies heavily on third-party CROs, CMOs, and collaborators, which creates execution, quality, and supply-chain risk in addition to the usual drug-development and competitive risks.
- Clinical development failure for JADE101Vaikutus: KriittinenTodennäköisyys: Kohtalainen
The company states it is substantially dependent on JADE101 and expects success to depend on IgA suppression and improved PK in humans.
Kohdistuu: Lead asset and near-term value driver
- Capital access and dilution riskVaikutus: KorkeaTodennäköisyys: Kohtalainen
The company expects substantial additional funding needs before product revenue and may need equity or other financing.
Kohdistuu: Operating runway and program continuity
- Third-party development and manufacturing dependenceVaikutus: KorkeaTodennäköisyys: Kohtalainen
Research, trials, and manufacturing are largely outsourced to CROs, CMOs, and collaborators.
Kohdistuu - Regulatory and trial-timing riskVaikutus: KorkeaTodennäköisyys: Kohtalainen
Delays or negative regulatory outcomes can shorten exclusivity and allow competitors to reach market first.
Kohdistuu - Cybersecurity and data integrity riskVaikutus: KeskitasoTodennäköisyys: Matala
Clinical and vendor data systems are exposed to breaches, outages, and unauthorized access.
Kohdistuu: Confidential data and trial operations
Kirjanpito
Harkinnanvaraiset erätThe company records study and manufacturing costs as incurred, so estimate changes can shift quarterly expenses.
Vaikutus: Affects operating loss timing and comparability
Personnel and warrant-related equity compensation is a notable expense for a pre-commercial biotech.
Vaikutus: Affects reported R&D and G&A costs
Cash, cash equivalents, and investments are central to assessing funding needs and going-concern risk.
Vaikutus: Affects liquidity analysis and financing expectations
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Crescent Biopharma, Inc
CBIO · Pharmaceutical Preparations
Adagene Inc.
ADAG · Pharmaceutical Preparations
Forte Biosciences, Inc.
Pharmaceutical Preparations
Corbus Pharmaceuticals Holdings, Inc.
CRBP · Pharmaceutical Preparations
GRI Bio, Inc.
GRI · Pharmaceutical Preparations
Inmune Bio, Inc.
INMB · Biological Products, (No Diagnostic Substances)
Päivitetty: 24.9.2026